VCYT
Veracyte, Inc.
NASDAQ · USHealthcareBiotechnology
$57.26-3.16%
Price as of Jul 20, 2026
VCYT financials
Veracyte, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $517.1M | $445.8M | $361.1M | $296.5M |
| Cost of revenue | $157.1M | $147.6M | $112.9M | $101.6M |
| Gross profit | $360.0M | $298.1M | $248.1M | $195.0M |
| Operating expenses | $285.9M | $282.0M | $333.9M | $236.0M |
| Operating income | $74.2M | $16.1M | -$85.8M | -$41.1M |
| Net income | $66.4M | $24.1M | -$74.4M | -$36.6M |
| EBITDA | $89.6M | $49.2M | -$49.4M | -$7.0M |
| Basic EPS | $0.84 | $0.32 | $-1.02 | $-0.51 |
| Diluted EPS | $0.82 | $0.31 | $-1.02 | $-0.51 |
| Balance sheet | ||||
| Cash & equivalents | $362.6M | $239.1M | $216.5M | $154.2M |
| Total assets | $1.4B | $1.3B | $1.1B | $1.2B |
| Total liabilities | $96.4M | $124.1M | $70.8M | $81.2M |
| Stockholders’ equity | $1.3B | $1.2B | $1.0B | $1.1B |
| Total debt | $39.7M | $50.7M | $12.6M | $14.7M |
| Net debt | -$322.9M | -$188.3M | -$203.8M | -$139.5M |
| Cash flow | ||||
| Operating cash flow | $136.3M | $75.1M | $44.2M | $7.5M |
| Capital expenditure | -$9.7M | -$11.3M | -$10.0M | -$8.5M |
| Free cash flow | $126.6M | $63.8M | $34.3M | -$1.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |